KYMR Stock Analysis Today
Updated Nov 12, 2026 · trends, key levels, insider activity and news
Is KYMR bullish or bearish today?
Daily trend: Uptrend (confirmed) — turns down below $99.52
SEPT signal: Accumulation · Strong Bullish
Research grade: C · fair value $94.06 (+8.3%)
KYMR trend by timeframe
| Daily | Uptrend (confirmed) |
|---|---|
| 4 hour | Leaning Bearish |
| 1 hour | Bearish |
| 15 min | Bearish |
| 5 min | Consolidating |
Trends are calculated from price structure and update during market hours.
KYMR support and resistance levels
Resistance (above)
$142.921 touches
Support (below)
$127.744 touches
$117.3113 touches
$109.056 touches
Upside zones: $125.09 / $128.11 / $131.13
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 1630-day net
—Hedge fund holders
248Latest KYMR news and filings
- AnalystFiscal.ai
Barclays keeps Overweight on Kymera Therapeutics, lifts price target
Barclays reiterated its Overweight rating on Kymera Therapeutics and increased its price target on the shares. The change reflects the analyst's updated view of the stock.
- AnalystBenzinga
Barclays keeps Overweight rating on Kymera Therapeutics, lifts target to $170
Barclays stayed positive on Kymera Therapeutics and raised its price target to $170. The rating and target are analyst views, not company results.
- AnalystBenzinga
Truist Securities keeps Buy rating on Kymera Therapeutics, lifts target to $150
Truist Securities repeated its Buy call on Kymera Therapeutics and moved its price target up to $150. The change reflects the firm's updated view on the stock.
- AnalystBenzinga
RBC Capital keeps Sector Perform on Kymera Therapeutics, lifts target to $116
RBC Capital kept its Sector Perform rating on Kymera Therapeutics and raised its price target to $116. The update reflects the analyst's revised view of the stock.
- EarningsFiscal.ai
Kymera Therapeutics releases Q3 2026 financials, reports encouraging KT-579 Phase 1 findings
Kymera Therapeutics published its quarterly financials for the third quarter of 2026. The company also said early-stage trial data for KT-579 came back favorable.
- SEC FilingSECKymera Therapeutics, Inc. filed a report on a major company event (Form 8-K)
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
Live KYMR chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is KYMR bullish or bearish today?
KYMR daily trend: Uptrend (confirmed) — turns down below $99.52. SEPT signal: Accumulation (Strong Bullish). Updated Nov 12, 2026.
What is KYMR's trend on each timeframe?
Daily: Uptrend (confirmed); 4 hour: Leaning Bearish; 1 hour: Bearish; 15 min: Bearish; 5 min: Consolidating.
What are KYMR support and resistance levels?
Support: $127.74, $117.31, $109.05. Resistance: $142.92. Last price $134.84.
Are insiders buying or selling KYMR?
Insider signal: Sell. Last 30 days: 0 buys, 16 sells. 248 hedge funds hold KYMR.
What is the latest news on KYMR?
Nov 2, 2026: Barclays keeps Overweight on Kymera Therapeutics, lifts price target · Nov 2, 2026: Barclays keeps Overweight rating on Kymera Therapeutics, lifts target to $170 · Oct 30, 2026: Truist Securities keeps Buy rating on Kymera Therapeutics, lifts target to $150